Entod Unveils World's First Losartan Eye Drops for Corneal Scarring

Entod Pharmaceuticals has announced a major breakthrough with the development of the world’s first losartan eye drops for treating corneal scarring, a leading cause of preventable vision loss worldwide. The innovation marks a significant step forward in global eye care therapeutics.

Losartan, commonly used as an oral antihypertensive drug, has recently shown strong anti-fibrotic and anti-scarring activity in corneal tissue, supported by published international research.

Entod’s R&D team successfully repurposed and stabilized the molecule into a topical ophthalmic formulation at its DSIR-approved R&D center in Navi Mumbai. Developed using the company’s proprietary EyeBS advanced ionic buffer technology, the formulation represents a global first in ophthalmic formulation science.

Also Read: Importance of Investing in R&D and Quality for Competitive Advantage in Eye Care

This advancement strengthens Entod Pharmaceuticals’ leadership in ocular drug delivery, advanced formulation design, and safer preservative systems. The company said it will soon begin the formal regulatory pathway in India, with clinical trials planned for early 2026 to assess safety, efficacy, and long-term outcomes of the losartan eye drops.

The process will involve approval from the Central Drugs Standard Control Organization (CDSCO) to initiate trials, followed by Drug Controller General of India (DCGI) approval for commercialization. The product will be marketed under the brand name Ocuzart and will be available by prescription only.

Dr K V Satyamurthy, senior consultant, M M Joshi Eye Institute, Dharwad said: “Corneal scarring caused by trauma, infections, or post-surgical complications remains one of the leading causes of irreversible vision loss … and improve visual rehabilitation — marking a long-awaited pharmacological advance in this domain.”

Nikkhil K Masurkar, CEO of Entod Pharmaceuticals, stated: “Corneal scarring affects millions, yet therapeutic progress has been stagnant. These eye drops have the potential to transform how ophthalmologists manage corneal healing and vision restoration. We are proud to reinforce India’s leadership in ophthalmic research, formulation science, and patient centric innovation.”